dexmedetomidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	835	113775-47-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexmedetomidine (S)-Medetomidine dexmedetomidine hydrochloride dexdor dexmedetomidine HCl MPV1440 precedex	A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound. Molecular weight: 200.29 Formula: C13H16N2 CLOGP: 3.10 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 28.68 ALOGS: -3.06 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexmedetomidine
(S)-Medetomidine
dexmedetomidine hydrochloride
dexdor
dexmedetomidine HCl
MPV1440
precedex

A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.

Molecular weight: 200.29
Formula: C13H16N2
CLOGP: 3.10
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 28.68
ALOGS: -3.06
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.09 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	20 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company
Dec. 17, 1999	FDA	HOSPIRA
Jan. 29, 2001	PMDA	Abbott Japan, Maruishi Pharmaceutical
Sept. 15, 2011	EMA	Orion Corporation

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	236.92	30.29	108	3953	73119	63411842
Product administered to patient of inappropriate age	119.31	30.29	30	4031	3238	63481723
Hypotension	87.69	30.29	97	3964	272507	63212454
Delirium	82.28	30.29	47	4014	50494	63434467
Agitation	80.07	30.29	49	4012	59708	63425253
Upper airway obstruction	78.07	30.29	16	4045	687	63484274
Floppy iris syndrome	76.08	30.29	12	4049	110	63484851
Respiratory depression	73.42	30.29	29	4032	13686	63471275
Glossoptosis	73.15	30.29	11	4050	71	63484890
Cardiac arrest	71.59	30.29	54	4007	92491	63392470
Withdrawal syndrome	69.21	30.29	31	4030	19966	63464995
Respiratory acidosis	69.05	30.29	23	4038	6692	63478269
Sinus arrest	61.83	30.29	16	4045	1933	63483028
Respiratory failure	56.61	30.29	49	4012	101809	63383152
Off label use	56.36	30.29	129	3932	674333	62810628
Generalised tonic-clonic seizure	55.44	30.29	30	4031	28986	63455975
Laryngeal stenosis	55.20	30.29	13	4048	1065	63483896
Tachyphylaxis	53.42	30.29	10	4051	266	63484695
Hepatic function abnormal	51.11	30.29	31	4030	37111	63447850
Stress cardiomyopathy	50.63	30.29	20	4041	9430	63475531
Drug reaction with eosinophilia and systemic symptoms	48.51	30.29	29	4032	33807	63451154
Local anaesthetic systemic toxicity	46.86	30.29	11	4050	888	63484073
Acute respiratory distress syndrome	46.82	30.29	25	4036	23509	63461452
Product closure removal difficult	44.43	30.29	6	4055	15	63484946
Hyperthermia	44.28	30.29	18	4043	9138	63475823
Ventricular dysfunction	42.77	30.29	13	4048	2815	63482146
Phaeochromocytoma crisis	41.65	30.29	8	4053	245	63484716
Myoclonus	40.68	30.29	20	4041	15848	63469113
Abdominal compartment syndrome	40.27	30.29	9	4052	584	63484377
Aplastic anaemia	40.16	30.29	17	4044	9552	63475409
Drug interaction	39.48	30.29	60	4001	229071	63255890
Unwanted awareness during anaesthesia	39.34	30.29	8	4053	330	63484631
Human herpesvirus 6 infection reactivation	38.53	30.29	8	4053	366	63484595
Laryngospasm	37.73	30.29	12	4049	3016	63481945
Posterior reversible encephalopathy syndrome	36.12	30.29	19	4042	17326	63467635
Device pacing issue	35.26	30.29	6	4055	91	63484870
Tachycardia	34.34	30.29	40	4021	118116	63366845
Hypernatraemia	33.54	30.29	14	4047	7595	63477366
Atrioventricular block second degree	30.88	30.29	11	4050	3903	63481058
Arteriospasm coronary	30.73	30.29	11	4050	3957	63481004
Postoperative ileus	30.62	30.29	7	4054	503	63484458
Accident at work	30.43	30.29	7	4054	517	63484444

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	371.60	24.32	207	6148	75211	34875365
Diabetes insipidus	267.56	24.32	69	6286	2859	34947717
Cardiac arrest	208.88	24.32	158	6197	96001	34854575
Hyperthermia	148.62	24.32	60	6295	10517	34940059
Intestinal pseudo-obstruction	144.05	24.32	38	6317	1718	34948858
Product administered to patient of inappropriate age	133.04	24.32	41	6314	3250	34947326
Arteriospasm coronary	115.32	24.32	37	6318	3345	34947231
Hyperthermia malignant	109.04	24.32	32	6323	2145	34948431
Drug withdrawal syndrome	101.42	24.32	56	6299	19778	34930798
Delirium	98.99	24.32	74	6281	43917	34906659
Hypotension	87.09	24.32	149	6206	221500	34729076
Seizure like phenomena	74.62	24.32	19	6336	745	34949831
Respiratory failure	71.32	24.32	93	6262	108479	34842097
Postoperative ileus	71.08	24.32	18	6337	690	34949886
Off label use	68.35	24.32	198	6157	419326	34531250
Serotonin syndrome	62.20	24.32	41	6314	19892	34930684
Acute motor axonal neuropathy	57.43	24.32	10	6345	55	34950521
Tachycardia	51.59	24.32	70	6285	84702	34865874
Burkholderia test positive	51.06	24.32	15	6340	1008	34949568
Sedation complication	50.72	24.32	17	6338	1760	34948816
Withdrawal syndrome	49.84	24.32	30	6325	12425	34938151
Electrocardiogram QT prolonged	47.17	24.32	47	6308	40905	34909671
Polyuria	45.98	24.32	25	6330	8549	34942027
Myoclonus	45.23	24.32	30	6325	14695	34935881
Epidermolysis bullosa	44.94	24.32	9	6346	115	34950461
Tachypnoea	43.75	24.32	32	6323	18320	34932256
Upper airway obstruction	43.31	24.32	12	6343	653	34949923
Drug ineffective for unapproved indication	42.68	24.32	35	6320	23680	34926896
Fatigue	40.54	24.32	9	6346	370644	34579932
Agitation	40.49	24.32	51	6304	57348	34893228
Malignant catatonia	38.79	24.32	9	6346	237	34950339
Torsade de pointes	38.60	24.32	21	6334	7188	34943388
Hyperaesthesia	37.99	24.32	18	6337	4612	34945964
Product use issue	36.61	24.32	51	6304	63165	34887411
Laryngomalacia	36.11	24.32	9	6346	323	34950253
Drug interaction	34.00	24.32	104	6251	225842	34724734
Product use in unapproved indication	33.45	24.32	69	6286	117430	34833146
Hypernatraemia	32.81	24.32	20	6335	8470	34942106
Floppy iris syndrome	31.53	24.32	8	6347	309	34950267
Multiple organ dysfunction syndrome	30.57	24.32	52	6303	76514	34874062
Urinary bladder rupture	29.19	24.32	6	6349	88	34950488
Cardiac arrest neonatal	28.79	24.32	5	6350	27	34950549
Sinus arrest	28.36	24.32	11	6344	1729	34948847
Haemodynamic instability	28.27	24.32	19	6336	9504	34941072
Neuroleptic malignant syndrome	27.20	24.32	24	6331	17910	34932666
Respiratory depression	27.19	24.32	23	6332	16222	34934354
Abdominal compartment syndrome	26.73	24.32	9	6346	944	34949632
Asthenia	26.67	24.32	6	6349	245245	34705331
Glossoptosis	26.55	24.32	6	6349	140	34950436
Drug withdrawal syndrome neonatal	26.46	24.32	13	6342	3606	34946970
Macule	26.19	24.32	10	6345	1507	34949069
Hypoxia	25.48	24.32	40	6315	55055	34895521
Transcranial electrical motor evoked potential monitoring abnormal	24.91	24.32	4	6351	12	34950564
Hypercapnia	24.47	24.32	13	6342	4242	34946334

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	472.77	25.06	260	9594	135297	79599237
Diabetes insipidus	272.89	25.06	73	9781	5164	79729370
Cardiac arrest	264.39	25.06	197	9657	171899	79562635
Product administered to patient of inappropriate age	204.65	25.06	59	9795	5494	79729040
Hyperthermia	187.68	25.06	74	9780	17963	79716571
Intestinal pseudo-obstruction	143.64	25.06	38	9816	2571	79731963
Delirium	138.92	25.06	101	9753	84526	79650008
Hypotension	137.56	25.06	216	9638	440101	79294433
Drug withdrawal syndrome	121.63	25.06	67	9787	34651	79699883
Arteriospasm coronary	112.06	25.06	39	9815	6677	79727857
Respiratory failure	111.32	25.06	124	9730	180787	79553747
Hyperthermia malignant	107.49	25.06	31	9823	2886	79731648
Respiratory depression	107.02	25.06	57	9797	27573	79706961
Postoperative ileus	106.33	25.06	25	9829	1040	79733494
Upper airway obstruction	104.02	25.06	26	9828	1402	79733132
Agitation	103.59	25.06	91	9763	99624	79634910
Withdrawal syndrome	102.89	25.06	55	9799	26799	79707735
Serotonin syndrome	88.40	25.06	60	9794	44967	79689567
Myoclonus	85	25.06	49	9805	27611	79706923
Off label use	84.33	25.06	274	9580	906941	78827593
Glossoptosis	79.01	25.06	15	9839	216	79734318
Polyuria	78.67	25.06	38	9816	14976	79719558
Tachypnoea	73.31	25.06	47	9807	32016	79702518
Tachycardia	72.32	25.06	99	9755	177669	79556865
Electrocardiogram QT prolonged	71.67	25.06	71	9783	90315	79644219
Generalised tonic-clonic seizure	71.06	25.06	52	9802	43858	79690676
Drug interaction	70.48	25.06	157	9697	415026	79319508
Drug ineffective for unapproved indication	70.35	25.06	55	9799	51183	79683351
Hypernatraemia	65.09	25.06	33	9821	14418	79720116
Seizure like phenomena	65.06	25.06	19	9835	1848	79732686
Sinus arrest	64.16	25.06	22	9832	3600	79730934
Abdominal compartment syndrome	63.45	25.06	18	9836	1579	79732955
Stress cardiomyopathy	57.70	25.06	28	9826	11138	79723396
Respiratory acidosis	57.62	25.06	28	9826	11172	79723362
Fatigue	56.96	25.06	22	9832	929705	78804829
Acute motor axonal neuropathy	55.58	25.06	10	9844	105	79734429
Arthralgia	55.40	25.06	4	9850	571799	79162735
Multiple organ dysfunction syndrome	51.96	25.06	69	9785	120177	79614357
Delayed recovery from anaesthesia	49.48	25.06	15	9839	1658	79732876
Hypoxia	48.90	25.06	62	9792	103181	79631353
Sedation complication	48.77	25.06	28	9826	15641	79718893
Torsade de pointes	48.37	25.06	30	9824	19282	79715252
Drug reaction with eosinophilia and systemic symptoms	48.21	25.06	49	9805	64195	79670339
Laryngeal stenosis	46.57	25.06	13	9841	1075	79733459
Atrioventricular block second degree	45.99	25.06	21	9833	7291	79727243
Product use in unapproved indication	45.01	25.06	97	9757	250262	79484272
Malaise	43.22	25.06	5	9849	489864	79244670
Ventricular tachycardia	42.95	25.06	38	9816	41897	79692637
Epidermolysis bullosa	42.93	25.06	9	9845	219	79734315
Nausea	42.26	25.06	34	9820	957162	78777372
Laryngospasm	40.15	25.06	16	9838	3981	79730553
Paradoxical drug reaction	40.11	25.06	19	9835	7166	79727368
Product closure removal difficult	40.00	25.06	5	9849	0	79734534
Headache	39.09	25.06	16	9838	653756	79080778
Haemodynamic instability	38.53	25.06	25	9829	17357	79717177
Local anaesthetic systemic toxicity	37.94	25.06	11	9843	1043	79733491
Ventricular fibrillation	36.89	25.06	31	9823	31895	79702639
Blood pressure decreased	36.83	25.06	53	9801	99413	79635121
Diarrhoea	36.73	25.06	33	9821	880456	78854078
Neuroleptic malignant syndrome	36.55	25.06	29	9825	27530	79707004
Malignant catatonia	36.55	25.06	9	9845	456	79734078
Hepatic function abnormal	36.36	25.06	45	9809	73062	79661472
Acute respiratory distress syndrome	35.61	25.06	35	9819	44032	79690502
Dizziness	34.65	25.06	11	9843	526430	79208104
Burkholderia test positive	34.50	25.06	9	9845	576	79733958
Phaeochromocytoma crisis	34.11	25.06	8	9846	329	79734205
Shock	34.10	25.06	34	9820	43514	79691020
Pain in extremity	34.01	25.06	3	9851	364535	79369999
Hyperpyrexia	33.67	25.06	16	9838	6076	79728458
Asthenia	33.13	25.06	11	9843	511678	79222856
Weight decreased	32.93	25.06	3	9851	355195	79379339
Transcranial electrical motor evoked potential monitoring abnormal	32.82	25.06	5	9849	16	79734518
Airway complication of anaesthesia	32.36	25.06	8	9846	412	79734122
Atrioventricular block complete	32.26	25.06	22	9832	16588	79717946
Drug ineffective	31.87	25.06	235	9619	1080678	78653856
Oxygen saturation decreased	31.64	25.06	57	9797	128990	79605544
Aplastic anaemia	30.76	25.06	22	9832	17883	79716651
Hyperaesthesia	30.64	25.06	19	9835	12203	79722331
Hypercapnia	30.60	25.06	17	9837	8918	79725616
Human herpesvirus 6 infection reactivation	29.86	25.06	8	9846	567	79733967
Anaphylactic shock	29.85	25.06	29	9825	35967	79698567
Septic shock	29.80	25.06	54	9800	122747	79611787
Device pacing issue	29.29	25.06	6	9848	130	79734404
Decreased appetite	28.95	25.06	4	9850	342414	79392120
Dyspnoea	28.17	25.06	39	9815	856986	78877548
Sinus bradycardia	28.11	25.06	24	9830	25223	79709311
Product use issue	26.55	25.06	71	9783	209751	79524783
Acute respiratory failure	25.44	25.06	34	9820	59507	79675027
Trigemino-cardiac reflex	25.21	25.06	6	9848	263	79734271

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05CM18	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives
FDA MoA	N0000009918	Adrenergic alpha2-Agonists
FDA EPC	N0000175554	Central alpha-2 Adrenergic Agonist
CHEBI has role	CHEBI:35569	alpha-adrenergic agonists
CHEBI has role	CHEBI:35717	hypnotics
FDA PE	N0000175975	General Anesthesia
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058647	Adrenergic alpha-2 Receptor Agonists
MeSH PA	D000316	Adrenergic alpha-Agonists
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Conscious sedation	indication	314271007
Complete atrioventricular block	contraindication	27885002
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Cardiac Decompensation	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Preanesthesia to general anesthesia	Indication
Cats	Sedation and analgesia	Indication
Dogs	Preanesthesia to general anesthesia	Indication
Dogs	Sedation and analgesia	Indication
Dogs	Noise aversion	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Dexdomitor	Orion Corp.	1
SILEO	Orion Corp.	1
Dexmedesed	Dechra Veterinary Products LLC	1
Dexmedetomidine Hydrochloride Injection	Akorn Animal Health Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.36	acidic
pKa2	6.76	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	March 13, 2013	RX	INJECTABLE	INJECTION	8455527	Jan. 4, 2032	USE FOR SEDATION
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	March 13, 2013	RX	INJECTABLE	INJECTION	8455527	Jan. 4, 2032	USE FOR SEDATION
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	Nov. 14, 2014	RX	INJECTABLE	INJECTION	8455527	Jan. 4, 2032	USE FOR SEDATION
EQ 0.12MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	10792246	June 26, 2039	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
EQ 0.12MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	11497711	June 26, 2039	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
EQ 0.12MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	11517524	June 26, 2039	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
EQ 0.18MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	10792246	June 26, 2039	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
EQ 0.18MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	11497711	June 26, 2039	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
EQ 0.18MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	11517524	June 26, 2039	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.12MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	April 5, 2025	NEW PRODUCT
EQ 0.18MG BASE	IGALMI	BIOXCEL	N215390	April 5, 2022	RX	FILM	BUCCAL, SUBLINGUAL	April 5, 2025	NEW PRODUCT
EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	Jan. 31, 2020	RX	INJECTABLE	INJECTION	Dec. 16, 2025	NEW PATIENT POPULATION
EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	Dec. 17, 1999	RX	INJECTABLE	INJECTION	Dec. 16, 2025	NEW PATIENT POPULATION
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	March 13, 2013	RX	INJECTABLE	INJECTION	Dec. 16, 2025	NEW PATIENT POPULATION
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	March 13, 2013	RX	INJECTABLE	INJECTION	Dec. 16, 2025	NEW PATIENT POPULATION
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	PRECEDEX	HOSPIRA	N021038	Nov. 14, 2014	RX	INJECTABLE	INJECTION	Dec. 16, 2025	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	AGONIST	Ki	9.70	IUPHAR	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	AGONIST	Ki	9.30	IUPHAR	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	AGONIST	EC50	8.82	CHEMBL	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	6.50	PDSP
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	6.70	PDSP
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	10.82	CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_RAT		Ki	10.82	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		EC50	6.42	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	10.82	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		Ki	8.30	CHEMBL
Alpha-1B adrenergic receptor	GPCR		G3HDX1_CRIGR		EC50	6.44	CHEMBL

External reference:

ID	Source
4021214	VUID
N0000148660	NUI
D00514	KEGG_DRUG
145108-58-3	SECONDARY_CAS_RN
228054	RXNORM
4021214	VANDF
4021215	VANDF
C0113293	UMLSCUI
CHEBI:4466	CHEBI
CZX	PDB_CHEM_ID
CHEMBL778	ChEMBL_ID
DB00633	DRUGBANK_ID
CHEMBL2106195	ChEMBL_ID
D020927	MESH_DESCRIPTOR_UI
5311068	PUBCHEM_CID
6277	INN_ID
521	IUPHAR_LIGAND_ID
67VB76HONO	UNII
227894	MMSL
29394	MMSL
31641	MMSL
8598	MMSL
d04505	MMSL
008084	NDDF
008085	NDDF
116348007	SNOMEDCT_US
437750002	SNOMEDCT_US
438079000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dexmedetomidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9525	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	31 sections
Dexmedetomidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9525	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	31 sections
Dexmedetomidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9526	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	31 sections
Dexmedetomidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9526	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	31 sections
Dexmedetomidine HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9532	INJECTION	100 ug	INTRAVENOUS	ANDA	30 sections
Dexmedetomidine HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9532	INJECTION	100 ug	INTRAVENOUS	ANDA	30 sections
DEXMEDETOMIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9555	INJECTION	200 ug	INTRAVENOUS	ANDA	32 sections
DEXMEDETOMIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9555	INJECTION	200 ug	INTRAVENOUS	ANDA	32 sections
DEXMEDETOMIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9555	INJECTION	200 ug	INTRAVENOUS	ANDA	32 sections
DEXMEDETOMIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9557	INJECTION	400 ug	INTRAVENOUS	ANDA	32 sections
DEXMEDETOMIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9557	INJECTION	400 ug	INTRAVENOUS	ANDA	32 sections
DEXMEDETOMIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9557	INJECTION	400 ug	INTRAVENOUS	ANDA	32 sections
PRECEDEX	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9938	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	18 sections
PRECEDEX	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9938	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	18 sections
PRECEDEX	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9938	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	18 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0155	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	31 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1174	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	37 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1174	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	37 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1174	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	37 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1434	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1434	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1434	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1434	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1454	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	37 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1454	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	37 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1454	INJECTION, SOLUTION	4 ug	INTRAVENOUS	NDA	37 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1638	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1638	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1638	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	36 sections
Precedex	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1638	INJECTION, SOLUTION, CONCENTRATE	100 ug	INTRAVENOUS	NDA	36 sections